Featured Publications
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medicationJoint analysis of repeatedly observed continuous and ordinal measures of disease severity
Gueorguieva RV, Sanacora G. Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics In Medicine 2006, 25: 1307-1322. PMID: 16217846, DOI: 10.1002/sim.2270.Peer-Reviewed Original Research
2017
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology 2017, 42: 2567-2574. PMID: 28553836, PMCID: PMC5686483, DOI: 10.1038/npp.2017.106.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSecondary efficacy outcomesEfficacy outcomesNeuroprotective effectsDepressive disorderResponse rateTreatment-resistant major depressive disorderMontgomery-Ã…sberg Depression Rating ScaleClinical Global Impressions-SeverityCurrent major depressive episodeDose of riluzolePlacebo/placeboSafety of riluzoleFixed-dose trialTreatment-resistant depressionSide effect profileGlutamate-modulating agentsMajor depressive episodeDepression Rating ScaleLack of efficacyPatient-reported measuresAmyotrophic lateral sclerosisSequential parallel comparison designRiluzole effectsAntidepressant efficacy
2011
Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses
Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses. JAMA Psychiatry 2011, 68: 1227-1237. PMID: 22147842, PMCID: PMC3339151, DOI: 10.1001/archgenpsychiatry.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsData Interpretation, StatisticalDepressive Disorder, MajorDouble-Blind MethodDuloxetine HydrochlorideFemaleHumansLinear ModelsMalePatient DropoutsPlacebo EffectPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexThiophenesTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsPlacebo-treated patientsComparator selective serotonin reuptake inhibitorsHAM-D scoresClinical trialsAntidepressant treatmentPlacebo responseMajor depressionDouble-blind clinical trialHigh placebo response rateSerotonergic antidepressant treatmentPlacebo response ratesSerotonin reuptake inhibitorsAntidepressant nonrespondersPlacebo armMost patientsAntidepressant respondersMedication risksReuptake inhibitorsSerotonergic antidepressantsResponder statusTreatment responseClinical trajectoriesDepression scoresDepression severity
2010
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2009
Adolescent cannabis use increases risk for cocaine-induced paranoia
Kalayasiri R, Gelernter J, Farrer L, Weiss R, Brady K, Gueorguieva R, Kranzler HR, Malison RT. Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug And Alcohol Dependence 2009, 107: 196-201. PMID: 19944543, PMCID: PMC2821949, DOI: 10.1016/j.drugalcdep.2009.10.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdolescent BehaviorAge FactorsAge of OnsetCannabisCatechol O-MethyltransferaseCocaine-Related DisordersFemaleGene FrequencyGenetic Predisposition to DiseaseHumansLogistic ModelsMaleParanoid DisordersPolymerase Chain ReactionPrevalencePsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexSiblingsUnited StatesConceptsAdolescent onset cannabisEarly cannabis exposureCocaine-dependent individualsCocaine-induced paranoiaCannabis exposureRisk factorsCOMT genotypeSemi-Structured AssessmentCatechol-O-methyl transferase (COMT) geneCOMT Val158Met genotypeCannabis abuseIncrease riskPsychotic symptomsOnset interactionPsychotic disordersStimulant abuseDrug dependenceFamily-based studyLogistic regressionEarly exposureAdolescent cannabisCannabisGenetic factorsSignificant predictorsVal158Met genotype
2006
Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs
Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang BZ, Farrer L, Gelernter J, Malison RT. Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug And Alcohol Dependence 2006, 84: 77-84. PMID: 16413147, DOI: 10.1016/j.drugalcdep.2005.12.002.Peer-Reviewed Original Research
2005
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. JAMA Psychiatry 2005, 62: 961-970. PMID: 16143728, DOI: 10.1001/archpsyc.62.9.961.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsBrief Psychiatric Rating ScaleDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePlacebosPsychotic DisordersRandomized Controlled Trials as TopicResearch DesignSchizophreniaSchizophrenic PsychologySelection BiasSeverity of Illness IndexSex FactorsTreatment OutcomeConceptsBrief Psychiatric Rating ScalePlacebo-controlled trialPsychiatric Rating ScalePlacebo-controlled studyAtypical antipsychotic medicationsDose-controlled studyMedication trialsAntipsychotic medicationRating ScaleDouble-blind clinical trialNew atypical antipsychotic medicationsDose-controlled trialsTreatment completion ratesPlacebo control groupEnd point changePercentage of menDrug Administration databaseRandom effects analysisIll adultsMedication armClinical trialsNew medicationsNovel medicationsSame drugAverage age
2004
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression. JAMA Psychiatry 2004, 61: 705-713. PMID: 15237082, DOI: 10.1001/archpsyc.61.7.705.Peer-Reviewed Original ResearchConceptsMajor depressive disorderGamma-aminobutyric acidOccipital cortex GABA concentrationsProton magnetic resonance spectroscopyDepressed subjectsGABA concentrationHealthy controlsSubtypes of MDDCortical gamma-aminobutyric acidHealthy control subjectsMetabolite levelsCholine-containing compoundsHealthy comparison subjectsClinical research programSubtype-specific alterationsΓ-aminobutyric acidClinical correlatesMDD patientsControl subjectsDepressive disorderNeurotransmitter levelsGlutamate levelsMajor depressionMDD subtypesOccipital cortex
2003
Posttraumatic Stress Disorder and Substance Use in Inner-City Adolescent Girls
Lipschitz DS, Rasmusson AM, Anyan W, Gueorguieva R, Billingslea EM, Cromwell PF, Southwick SM. Posttraumatic Stress Disorder and Substance Use in Inner-City Adolescent Girls. The Journal Of Nervous And Mental Disease 2003, 191: 714-721. PMID: 14614338, DOI: 10.1097/01.nmd.0000095123.68088.da.Peer-Reviewed Original ResearchConceptsInner-city adolescent girlsSubstance use disordersProblematic substance useSubstance useAdolescent girlsPosttraumatic stress disorder (PTSD) symptomsPosttraumatic stress symptomsPosttraumatic stress disorderComorbid substance use disorderTrauma exposureSubset of girlsTraumatized girlsDisorder symptomsStress disorderStress symptomsRate of nicotinePTSDPartial PTSDPsychiatric diagnostic interviewDiagnostic InterviewAlcohol useHospital-based adolescent clinicGirlsAdolescent clinicMarijuana